Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Therapeutic management of severe relapses in multiple sclerosis.
A prospective study of patients with brain MRI showing incidental t2 hyperintensities addressed as multiple sclerosis: a lot of work to do before treating.
Decreased Frequency of Circulating Myelin Oligodendrocyte Glycoprotein B Lymphocytes in Patients with Relapsing-Remitting Multiple Sclerosis.
Biotinidase deficiency mimicking neuromyelitis optica: Initially exhibiting symptoms in adulthood.
SNPsea: an algorithm to identify cell types, tissues, and pathways affected by risk loci.
Crying and suicidal, but not depressed. Pseudobulbar affect in multiple sclerosis successfully treated with valproic acid: Case report and literature review.
Bevacizumab is safe in acute relapses of neuromyelitis optica.
Vitamin D During Pregnancy and Multiple Sclerosis: An Evolving Association.
Comparative effect of 25(OH)D3 and 1,25(OH)2D3 on Th17 cell differentiation.
Whole-brain atrophy: ready for implementation into clinical decision-making in multiple sclerosis?
Association of TIM-1 5383-5397ins/del and TIM-3 -1541C>T polymorphisms with multiple sclerosis in Isfahan population.
Therapeutic options in neuromyelitis optica spectrum disorders.
Safety and efficacy of hematopoietic stem cells mobilization in patients with multiple sclerosis.
Thyroid Hormone Potentially Benefits Multiple Sclerosis via Facilitating Remyelination.
Anti-inflammatory mechanisms of IFN-γ studied in experimental autoimmune encephalomyelitis reveal neutrophils as a potential target in multiple sclerosis.
Retinal ganglion cell layer thinning within one month of presentation for optic neuritis.
Differential diagnosis and prognosis for longitudinally extensive myelitis in Buenos Aires, Argentina.
Altered cognitive-emotional behavior in early experimental autoimmune encephalitis - Cytokine and hormonal correlates.
Vitamin d as a potential therapy in amyotrophic lateral sclerosis.
Evaluation of commercial antibodies against human sphingosine-1-phosphate receptor 1.
The Nuclear IκB Family Protein IκBNS Influences the Susceptibility to Experimental Autoimmune Encephalomyelitis in a Murine Model.
Statin treatment 0061ffects cytokine release and phagocytic activity in primary cultured microglia through two separable mechanisms.
Exercise as a therapy for improvement of walking ability in adults with multiple sclerosis: A meta-analysis.
Neuromyelitis optica spectrum disorders without and with autoimmune diseases.
Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event.
Pages
« first
‹ previous
…
641
642
643
644
645
646
647
648
649
…
next ›
last »